New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
07:33 EDTMNKDMannKind shares may 'overshoot to the upside,' says JPMorgan
JPMorgan believes shares of MannKind may "overshoot to the upside" following the positive FDA panel vote given the significant short interest in the name as well as the company’s "passionate" retail following. JPMorgan remains concerned about the commercial potential of Afrezza and keeps a Neutral rating on MannKind.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use